RATIONALE-307
Regimen
- Experimental
- tislelizumab + paclitaxel/nab-pac + carbo
- Control
- paclitaxel + carbo
Population
Chinese 1L sq NSCLC
Key finding
mPFS 7.6 vs 5.5 mo, HR 0.524 (0.370-0.742); tislelizumab 1L sq
Source: PMID 33792623
Timeline
- Enrollment start: 2018-07-30 📎
Guideline citations
- CSCO NSCLC 2025 ⚠️ OCR source